In NSCLC, with either wild-type or mutant EGFR, inhibiting EGFR or MAPK reduces MET activation and protein levels, highlighting the critical role of EGFR-MET signaling in the aggressive behavior of NSCLC and its potential as a therapeutic target [18]. The gene discussed is MET; the disease is non-small cell lung carcinoma.